Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Head & Neck 1Gynecologic 1

Conditions

Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Adenocarcinoma 1

Interventions

Oxaliplatin 152Fluorouracil 137Gemcitabine 118Bevacizumab 116Leucovorin 106Specimen Handling 105Capecitabine 96pembrolizumab 90Magnetic Resonance Spectroscopy 83Nivolumab 79Cisplatin 79Irinotecan 71durvalumab 64Cetuximab 62Biopsy 61Paclitaxel 60130-nm albumin-bound paclitaxel 59Radiotherapy 46atezolizumab 45Albumin-Bound Paclitaxel 37Taxes 36Carboplatin 36Folfox protocol 35Drug Therapy 32Cyclophosphamide 30lenvatinib 29dehydroftorafur 29tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Losartan × Gastrointestinal × 90 days × Clear all
NCT05365893 2026-05-22

PHL Treatment in Pancreatic Cancer

Fox Chase Cancer Center

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT04106856 2026-05-12

SHAPER

University of Utah

Phase 1 Active not recruiting
22 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05077800 2026-04-13

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
70 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡